Phase 1Upstream
01Preparation of producer cells (cell banking and expansion) (cell banking / expansion culture)
The step that standardizes HEK293T properties and secures a large supply, setting the starting point of production that suppresses lot-to-lot variability.
- Standard method
- Master/working cell banking of HEK293T, and adaptation and expansion to serum-free suspension culture
Why it is the standard. The majority of clinical and commercial lots start from HEK293T. Moving to suspension and serum-free is the standard direction for scale-up and regulatory compliance (avoiding serum-derived risk), and cell bank management follows the thinking of ICH Q5A/Q5D.
With Stable producer cell line (inducible)
- Induction at high cell density and continuous production and harvest by perfusion are assumed, so the culture mode and cell retention device change.
- Method: After seed train expansion, cells are grown at induction to high cell density (~10–12×10^6 cells/mL, or high-density attachment to a fixed bed) and the culture moves to perfusion / pseudo-perfusion mode.
- Equipment: Perfusion bioreactor with a cell retention device (ATF/TFF), or fixed-bed bioreactors such as Scale-X Hydro/Carbo and iCELLis
- Check also: Optimization of the perfusion rate (VVD) limits the titer (because the half-life of LV is short, harvest titer drops at low VVD).
About this step and the alternatives
Lentiviral vectors are made by human-derived cells called HEK293T. This step formally registers these "workers" as the starting material.
The cells of uniform properties are frozen and banked in two tiers, the original master and the working bank for daily use. They are also adapted to grow in suspension without serum.
The more uniform the starting cells, the smaller the lot-to-lot swings in titer and quality. It can be called foundation work that decides quality at the very top of manufacturing.
Lentivirus is made in HEK293T-derived cells. Expanding cells of uniform properties in large quantity is the starting point for suppressing lot-to-lot variability.
Alternatives in practice
- Maintenance and expansion of adherent HEK293T · Thermo Fisher Nunc Cell Factory (multilayer) / Corning CellSTACK; medium Gibco DMEM + FBS (e.g., Gibco 10% FBS) — For small to mid scale and transient production. Serum-containing, so scale-up and serum-free adaptation are issues
- Stable packaging / producer cell lines · GMP stable LV cell line platforms such as those of Cevec/WuXi (e.g., Oxford Biomedica TetraVecta-type / in-house lines) — No plasmids required and high batch-to-batch reproducibility. Line construction takes time
- Semi-stable (partly stabilized elements) cell line · In-house derived line with Gag-Pol/Rev stabilized and only VSV-G and the transgene introduced transiently — A compromise between reducing plasmid number and cost and keeping flexibility
Expansion and seeding of producer cells (seed train) → WCB is thawed and HEK293T are expanded stepwise to transfection scale, N-1 seeding
The thawed cell bank must be expanded to the production-scale cell density before the transfection step can begin.
- Standard method
- Seed train expansion in serum-free suspension culture in single-use bioreactors
Why it is the standard. Seed trains with suspension HEK293 lines are standard in GMP lentivirus manufacturing, and stepwise expansion in single-use bioreactors excels in cross-contamination risk and scalability
With Stable producer cell line (inducible)
- The core of this modality's branching. Plasmid/PEI transient introduction is eliminated entirely and production is started by chemical induction, so the standard method, reagents and equipment philosophy are all replaced.
- Method: Instead of PEI transient transfection with 3–4 plasmids, an inducer is added to the medium to activate transcription of the integrated genes and induce vector production (doxycycline added for Tet-on, removed for Tet-off).
- Equipment: The steps of plasmid preparation, PEI complex formation and addition, and the related equipment, are unnecessary
- Reagents: Doxycycline (1–2 μg/mL) + cumate (10–30 μg/mL), or doxycycline + sodium butyrate (5 mM). Plasmid DNA and PEI are not used.
- Check also: Risk assessment of RCL generation through recombination between integrated components and host DNA remains important (a design to avoid it is essential even in inducible systems).
About this step and the alternatives
A step in which cryopreserved cells are thawed and, rather than going straight to the main run, gradually expanded to build a run-up. It is called the "seed train" and works like the run-up before a track start.
The procedure is to expand while moving up in stages from a small shake flask to a somewhat larger culture vessel. While the cells are growing vigorously, they are brought to the target cell density (e.g., 200 × 10^4 = 2 million cells per 1 mL).
The small number of cells right after thawing is brought, in one continuous run, to the scale and volume at which the next vector production can begin. It is an unglamorous but indispensable run-up section that affects the yield of the main run.
Transfection at production scale immediately after thawing a WCB is impossible, so a stepwise expansion from shake flasks to a seed bioreactor (seed train) up to the target cell density and volume is essential. Transfection is started when the target density (e.g., 2×10^6 cells/mL) is reached in the exponential growth phase.
Alternatives in practice
- Adherent expansion in multilayer cell factories · Thermo Fisher Nunc Cell Factory (4–40 layers) / Corning CellSTACK, HYPERStack — For seed expansion of adherent processes. Labor-intensive and hard to automate
- Seed expansion in wave-type (rocking) single-use bioreactors · Cytiva ReadyToProcess WAVE 25 (Cellbag 2–25 L) or Sartorius Biostat RM — Low shear, well suited to suspension seed expansion. Standard as the stage before a stirred tank
- Integrated expansion and production in a fixed-bed bioreactor · Cytiva (formerly Pall) iCELLis Nano / 500+ or Univercells Technologies scale-X carbo/hydro — Integrates expansion and production in an adherent system. High specific surface area gives high titer
Vector production (transient transfection + bioreactor culture) (main culture / vector production)
The rate-limiting step in which multiple plasmids are introduced simultaneously to make vector particles, and the titer harvested is almost determined here.
- Standard method
- PEI transient transfection with a 3–4 plasmid system
Why it is the standard. Most clinical lots use the 3rd-generation, 4-plasmid transient method. PEI has replaced the calcium phosphate method as the industry standard for its safety and scalability. iCELLis is a fixed-bed platform widely used for GMP large-scale production.
Check also. Transient transfection, in which multiple plasmids are introduced afresh for every lot, is the mainstream for clinical lots but is not the one absolute standard. Titer tends to swing between lots with plasmid quality and transfection efficiency, and for commercial large-scale production an inducible stable producer cell line is also a strong option.
With Stable producer cell line (inducible)
- Instead of a single batch harvest at 48 h/72 h as in the transient system, harvesting is continuous and multiple by perfusion, so the harvest mode changes.
- Method: After induction, vector-containing supernatant is harvested continuously through the perfusion line over several days (~4–6 days; around 7 harvests with a fixed bed), clarified continuously, and stored sequentially at -80 °C.
- Equipment: Perfusion harvest line + in-line clarification (TFF-type depth filtration such as TFDF used together with cell retention)
- Check also: Because harvesting is continuous, the titer of each harvest fraction varies over time, and pooling timing must be managed.
About this step and the alternatives
This is the heart of manufacturing. The gene of interest and 3–4 blueprints (plasmids) for making the viral shell and enzymes are carried into the cells at the same time to make them produce vector particles.
The carrier is a reagent called PEI, in a mode that introduces the genes temporarily (transient introduction). After introduction, the cells in the culture vessel diligently secrete vector.
The amount of vector harvested, that is, the titer, is almost determined by this step. Small differences in conditions affect the yield, which makes it the core stage of the whole manufacture.
The gene of interest and multiple plasmids that make the viral shell and enzymes are put into the cells at the same time to make them produce vector particles. The titer (the amount that can be harvested) is almost determined here.
Alternatives in practice
- Calcium phosphate co-precipitation transfection · Reagent preparation only (CaCl2 + 2×HBS, e.g., Takara CalPhos Mammalian Transfection Kit 631312) — Low cost, but pH-sensitive and inferior in large-scale reproducibility
- Induced production in a stable producer cell line · Stable LV cell line with a tetracycline/doxycycline-inducible system (in-house / Oxford Biomedica, etc.), inducer Sigma Doxycycline hyclate (D9891) — No plasmids or PEI needed, reducing CoG. Requires line construction first
- Perfusion production with suspension HEK293 · Cytiva XDR-50 + ATF (Repligen XCell ATF 4/6) or alternating tangential flow / TFF perfusion — High cell density and continuous harvest improve productivity. Control is complex
Recovery of vector-containing supernatant and medium exchange (harvest) → vector-secreting supernatant is recovered 48/72 hours after transfection, with medium exchange as needed and multiple harvests pooled
Lentivirus is secreted into the culture supernatant, so a step of recovering and pooling the supernatant separately from the producer cells is essential.
- Standard method
- Culture supernatant recovery 48 and 72 hours after transfection + medium exchange
- Reagents and materials
- The recovered supernatant is held at 2–8 °C and goes directly to clarification. If needed for pH/stabilization, a stabilizer is added immediately before (e.g., MgCl2 for Benzonase digestion, or correction of neutral Tris buffering). Dedicated reagents are usually unnecessary.
Why it is the standard. Lentivirus is secreted into the supernatant and has a short half-life, so rapid recovery and pooling of the supernatant at low temperature, as a step separate from clarification, is essential to maintain titer
About this step and the alternatives
Lentiviral vector does not accumulate inside the cells but is secreted into the culture fluid. That is why, before purification, the supernatant is first recovered whole.
The procedure is to collect the supernatant at milestones such as 48 and 72 hours after introduction. Fresh medium is put in, collection is repeated several times, and the collections are combined (pooled) and handed to downstream.
This vector has a short life and is sensitive to heat, so it loses activity if there is any delay. Recovering and holding it quickly at low temperature is the key to protecting the final yield.
Lentiviral vector is an enveloped virus secreted into the culture supernatant, not retained inside cells, so a step of recovering the supernatant at time points such as 48 and 72 hours after transfection (with multiple harvests after exchange to fresh medium as needed) and pooling it is always included as the front end of downstream processing. Because the half-life is short and the vector is temperature-sensitive, it is recovered and held quickly at low temperature.
Alternatives in practice
- Continuous harvest by perfusion · Repligen XCell ATF 4/6 (alternating tangential flow) or hollow fiber perfusion filter + Cytiva/Sartorius skid — Continuously recovers LV, which is sensitive to shear, shortening residence time. Equipment is complex
- Supernatant recovery after cell removal by centrifugation · Continuous centrifugation: Cytiva (formerly Pall) kSep or Alfa Laval/GEA continuous disc-stack centrifuge — Effective as pretreatment for high particle loads. Mind equipment cost and shear
Phase 2Downstream
05Clarification (removal of cells and debris) (clarification)
Removes cells and fragments to prevent downstream clogging, but with a 30–40% loss of activity, so the choice of conditions is the key in this step.
- Standard method
- Clarification by depth filtration + 0.45–0.8 μm membrane filtration
- Reagents and materials
- — (prefilters / filter membranes only). LV is negatively charged, so positively charged diatomaceous earth types (e.g., Millistak+ C0HC) lower recovery; choose grades without inorganic filter aids (e.g., Millistak+ CE50).
Why it is the standard. Depth + membrane filtration is the standard for primary clarification of both suspension and adherent cultures. As an alternative to centrifugation it is closed and scalable, and is the mainstream configuration in GMP manufacturing. A vector activity loss of about 30–40% in clarification has been reported, so condition optimization is emphasized.
Check also. Clarification is a step in which roughly 30–40% (3–4 out of 10) of vector activity is easily lost, and the choice of filter media and conditions greatly affects recovery. Lentivirus is negatively charged, so depth filters containing positively charged diatomaceous earth tend to lower recovery through adsorption, and grades without inorganic filter aids are chosen.
About this step and the alternatives
The recovered culture fluid contains the cells themselves and fragments of broken cells. This step removes them by filtration and turns the cloudy liquid into a clear one.
The procedure combines depth filtration, which captures by thickness, with fine-pored membrane filtration. It prevents clogging of downstream filters and columns.
The troublesome part is that the vector itself is easily lost in this clarification. The recovery rate changes with the choice of filter media and conditions, so it is a passage that cannot be taken lightly.
The culture fluid contains cells and fragments. These are removed so that downstream filters and columns do not clog. However, vector is easily lost during clarification, so the choice of conditions is the key.
Alternatives in practice
- Continuous centrifugation · Cytiva (formerly Pall) kSep 400/6000 or GEA continuous disc-stack centrifuge — Primary clarification of high-cell-density harvests. Shear management is needed
- Depth filter only (membrane omitted) · Merck Millipore Millistak+ CE single-layer depth (coarse clarification grade) — Simplifies the process. Downstream bioburden control is strengthened separately
- Combined in-culture pretreatment (DNase addition) · Roche Pulmozyme (dornase alfa, rhDNase I) or Merck Benzonase added directly before clarification — Reduces viscosity and clogging, and also reduces total DNA
Nuclease treatment (degradation of residual DNA) (nuclease digestion)
Fragments residual host DNA and plasmid enzymatically to keep the amount and fragment length of DNA in the final drug product at or below regulatory values.
- Standard method
- Nuclease digestion with Benzonase (before or after clarification, in the presence of Mg2+, 37 °C)
- Equipment
- — (added directly to the bioreactor or clarified fluid; digested at 37 °C under agitation in a Sartorius Flexsafe mixing bag).
Why it is the standard. Benzonase is the standard enzyme that broadly degrades host DNA, residual plasmid, RNA and free nucleic acids. As a guide, residual DNA is generally <10 ng per 1 dose with fragments <200 bp (FDA/WHO thinking), which lowers the risk of residual functional ORFs.
Check also. While it lowers residual DNA, the added Benzonase itself remains as a process-related impurity, so items for measuring residual enzyme increase downstream. When the host cell is HEK293T, stricter residual DNA control may be required depending on product risk because of oncogenicity concerns.
About this step and the alternatives
DNA from host cells and plasmid DNA used for introduction remain in the production fluid. This is the step that chops them into small pieces with enzyme scissors.
The enzyme used is Benzonase. It works well in the presence of magnesium ions at 37 °C. It is performed before or after clarification, whichever is convenient for the process.
By keeping DNA as short fragments, both the amount and the length of residual DNA carried into the final drug product can be kept below the levels set by regulation. It is a move directly tied to safety.
Host cell DNA and plasmid DNA remain in the production fluid. These are cut into small pieces with an enzyme to keep the amount and fragment length of DNA carried into the final drug product at or below regulatory values.
Alternatives in practice
- Alternative nuclease (GMP) · c-LEcta DENARASE (high-purity endonuclease) or Merck/Sigma Pulmozyme-type rhDNase — An alternative source of Benzonase; chosen to avoid residual-reagent ELISA or for price
- Enhanced digestion by optimizing salt concentration and treatment time · — (DoE optimization of NaCl concentration, temperature, enzyme amount and time; equipment is the existing mixer) — Reduces residual nucleic acid further. Balance with viscosity and recovery must be adjusted
- Reliance on DNA separation in the chromatography step (minimizing enzyme) · Enhanced DNA separation with strong anion exchange membranes (Pall Mustang Q / Sartobind Q) — Minimizes enzyme use and residual reagent. DBC/separation conditions need to be worked out
Intermediate purification and concentration (ultrafiltration/diafiltration) (ultrafiltration / UF/DF)
Concentrates the culture fluid and removes low-molecular-weight impurities by buffer exchange, gently bringing it to a state suited to the next column step.
- Standard method
- Concentration and buffer exchange by hollow fiber tangential flow filtration (TFF)
Why it is the standard. Hollow fiber TFF has relatively low shear stress and is suited to concentration and buffer exchange of LV. Placing TFF before chromatography allows removal of low-molecular-weight impurities, concentration and buffer exchange in one step, and is the standard configuration for large-scale processes.
About this step and the alternatives
A step that "boils down" a large volume of dilute culture fluid into a small, manageable volume. At the same time, the surrounding salts and low-molecular-weight impurities are replaced wholesale along with the buffer.
The procedure is TFF (tangential flow filtration), which flows the liquid tangentially along a hollow-fiber membrane. Flowing across the membrane surface suppresses clogging and handles concentration and buffer exchange at the same time.
The vector is sensitive to shear (the dragging force) and high salt concentration, so it is handled gently, without hard rubbing. This is a bridging step that brings the material to a state convenient for the next column step.
Concentrates a large volume of culture fluid into a small one and exchanges salts and low-molecular-weight impurities along with the buffer. It serves to bring the material to a state suited to the next column step. The vector is sensitive to shear and high conductivity, so it is done gently.
Alternatives in practice
- Flat-sheet TFF cassettes · Merck Millipore Pellicon 3 / Pellicon Capsule (Ultracel/Biomax) or Sartorius Sartocon/Hydrosart — Large surface area and high flux. Shear is somewhat higher than with hollow fiber, but robust
- Ultracentrifugation (density gradient) · Beckman Coulter Optima XPN ultracentrifuge + iodixanol (Cytiva OptiPrep) gradient — High purity and useful for evaluating the empty/full ratio. Scale-up is difficult, so for research / characterization
- Combined size exclusion chromatography (SEC) · Cytiva Sephacryl S-500 HR / Capto Core 700 + ÄKTA process — Serves for both buffer exchange and impurity separation. Limited by dilution and throughput
Conditioning before AEX load and bioburden-reduction filtration → conductivity is adjusted with dilution buffer and the column is protected with a 0.45 μm filter before loading onto anion exchange (conditioning)
A pretreatment that is essential: dilute to a conductivity suited to AEX binding and remove contaminating particles to prevent column clogging.
- Standard method
- Load conductivity adjustment with dilution buffer
Why it is the standard. The concentrate after TFF has high conductivity and AEX binding is insufficient, so dilution adjustment is essential, and pre-filtration prevents clogging of the membrane adsorber and stabilizes capture yield
About this step and the alternatives
The prep work before loading the next column (anion exchange). The just-concentrated liquid is high in salt, and the vector does not stick well to the resin as it is.
So it is thinned about 1:1 with dilution buffer to lower the salt concentration (conductivity) and bring it to a state in which binding is easy. Particles and microbes that remain are also removed by 0.45 μm filtration.
This extra step prevents column clogging and evens out the effectiveness of the capture step that follows. It is unglamorous, but acts as a warm-up exercise so that recovery is not lost.
The concentrated intermediate has high conductivity as it is, and lentivirus does not bind sufficiently to the anion exchanger, so conditioning, in which the load conductivity is adjusted by diluting about 1:1 with dilution buffer, is a standard requirement. In addition, 0.45 μm pre-filtration removes residual particles and bioburden and prevents column fouling.
Alternatives in practice
- Load conductivity adjustment by in-line dilution · In-line dilution on Cytiva ÄKTA process / ÄKTA ready, or in-line dilution on Sartorius Resolute BioSC — No pre-dilution tank needed, keeping process volume down. Depends on pump accuracy
- Bioburden reduction with stepwise 0.45/0.2 μm filters · Sartorius Sartopore 2 (0.45 + 0.2 μm dual-layer capsule) or Merck Millipore Millipak/Express SHC — Strengthens bioburden reduction before loading. Membrane selection is needed to be compatible with recovery
Capture and purification (ion exchange chromatography) (capture / purification)
Adsorbs negatively charged particles onto an anion membrane to separate them from impurities, but this is a difficult step with the lowest recovery downstream.
- Standard method
- Capture and purification by strong anion exchange (AEX) membrane chromatography
Why it is the standard. Membrane chromatography has low mass transfer resistance and back pressure and is suited to purifying large particles such as LV. Mustang Q / Sartobind Q are strong AEX membranes widely adopted for LV. AEX is regarded as the step with the lowest recovery downstream, and condition optimization is important.
Check also. Anion exchange is a difficult step where recovery tends to be lowest downstream, and binding and elution conditions depend strongly on the envelope and conductivity. If yield does not improve even after the conditions are worked out, switching to a capture method based on a different principle, such as the heparin affinity of VSV-G pseudotypes, should also be considered.
About this step and the alternatives
A step that scoops only the target vector out of a sea of impurities. The key is that the surface of vector particles is negatively charged. They are made to stick to a positively charged column and held.
The procedure is to adsorb the vector once onto a positively charged anion exchange (AEX) membrane, wash away the impurities, then change the conditions so that only the vector is eluted.
However, this capture is the difficult step where recovery is most likely to drop in downstream. Working out the conditions so that the hard-won vector is not lost separates quality and yield.
Using the property that the surface of vector particles is negatively charged, the vector is adsorbed onto a cationic membrane to separate it from impurities, and only the target vector is eluted. This is a difficult step where recovery tends to be lowest in downstream.
Alternatives in practice
- Nanofiber anion exchange chromatography · Cytiva Fibro (a Q-functionalized unit, not the HiTrap Fibro PrismA type) or Astrea Bioseparations Nanofiber Q (formerly Puridify) — Very short cycles and high flow rate with low shear on large particles. Capacity is in the same range as membranes
- Size exclusion chromatography (preparative SEC) · Cytiva Sephacryl S-500 HR / Capto Core 700 + ÄKTA process — Gentle and useful for separating impurities and empty capsids. Limited by throughput and dilution
- Affinity ligand purification · Cytiva Capto Heparin / Heparin Sepharose (using the heparin affinity of VSV-G pseudotyped LV) — High selectivity, but binding capacity and elution conditions need to be worked out
Phase 4Quality attributes and analytics
11Measurement of physical titer (total particle amount) (physical titer / p24)
Quantifies total particle amount with p24 antigen for yield control and the ratio to infectivity, but it is an indicator that must be distinguished from infectivity.
- Standard method
- Physical titer measurement by p24 (HIV-1 Gag capsid) antigen ELISA
Why it is the standard. p24 ELISA can quantify total particle amount in a few hours and is the representative reference method for LV physical titer. A conversion of about 1×10^4 physical particles per 1 pg of p24 (equivalent to about 100 TU) is widely cited. However, it also picks up inactive particles and free p24, so it must be distinguished from infectivity.
Check also. The p24 antigen ELISA also picks up broken particles and free p24, so it does not match the amount of infectious particles. Use it as the total particle amount itself and always read it alongside the infectious (functional) titer as a separate thing.
About this step and the alternatives
A test that counts "how many vector particles could be made". The amount of a protein called p24, a part of the particle shell, is read out by an immunoassay called ELISA.
What is measured here is the "total amount", separate from whether the particles can infect. The image is of counting particles with empty contents included, and it is used to manage how much yield the process gave.
Taking the ratio to the infectious titer measured later shows what proportion of the particles made are truly effective. The physical titer is the reference value that serves as the denominator in that quality evaluation.
Measures how many particles were produced. It is an indicator of the "total amount", separate from infectivity, and is used for yield control of the process and for the ratio to infectivity (a quality indicator).
Alternatives in practice
- Genomic RNA copy number measurement by RT-qPCR · Bio-Rad CFX96 / Applied Biosystems QuantStudio + Takara Lenti-X qRT-PCR Titration Kit (631235) — Quantifies genome-containing particles. A separate indicator from infectious titer, so correlation must be confirmed
- Nanoparticle tracking analysis · Malvern Panalytical NanoSight Pro / NS300 — Directly measures total particle number and size. Quality is evaluated by the ratio of p24 to total particles
- Reverse transcriptase activity assay (PERT/SG-PERT) · Real-time PCR (Bio-Rad CFX96 / QuantStudio) + SG-PERT assay reagents — Estimates particle amount with high sensitivity from RT activity. Standardization and calibration are required
Measurement of infectious (functional) titer (infectious titer)
Quantifies integrated provirus copy number to measure the amount of working vector; the most important titer, directly tied to dose setting.
- Standard method
- After transduction of target cells, quantification of integrated provirus copy number by qPCR/ddPCR
Why it is the standard. Measuring integrated provirus copy number in the genome of transduced cells by PCR is the standard for functional titer. ddPCR enables absolute quantification independent of a standard curve and is strong in low-copy detection. When a reporter is carried, TU measurement based on % positive by FCM is also used.
About this step and the alternatives
The most important titer test, which measures not the total amount but "how much vector actually works". It is confirmed by actually having target cells take up the gene.
The procedure is to quantify, after transduction, the copy number of the gene integrated into the cell genome by qPCR/ddPCR. This is read as the number of vectors that were able to work.
This infectious titer is directly tied to dose design. Taking the ratio to the physical titer further shows the quality of the particles made directly as a number.
Measures how much vector can actually enter cells and work. It is the most important titer, directly tied to dose setting, and the ratio to the physical titer indicates how good the quality is.
Alternatives in practice
- Fluorescent reporter (GFP) + flow cytometry · GFP-positive rate of target cells measured with BD FACSCanto II / Beckman Coulter CytoFLEX — Directly measures transducing units (TU). Limited to GFP-carrying vectors
- Infectious titer by qPCR (standard curve method) · Bio-Rad CFX96 / Applied Biosystems QuantStudio + provirus TaqMan assay — For sites without ddPCR. Preparation of a standard curve and calibration are needed
- Titer by limiting dilution · Serial dilution culture of target cells + colony/transduction counting (microscope/imager, e.g., Molecular Devices ImageXpress) — Classical and low cost, but labor-intensive and highly variable
Identity, transgene expression and vector copy number (VCN) (identity / VCN)
Confirms the presence of the correct gene, its expression and the copy number per cell, assuring product identity and managing insertional mutagenesis risk.
- Standard method
- VCN measurement by ddPCR/qPCR, and transgene sequence and expression
Why it is the standard. VCN is a core indicator of the safety and efficacy of LV and LV-modified cells, and absolute quantification by ddPCR is becoming standardized. Identity is assured by confirming sequence (NGS/Sanger) and expression (RT-qPCR/FCM/WB) by separate methods.
About this step and the alternatives
A test that supports "the correct gene is in there and working properly". The copy number of vector entering 1 cell (VCN) is measured by ddPCR/qPCR.
The sequence of the delivered gene and whether the gene is properly expressed are also confirmed. This is evidence of identity, that the product is as intended.
Copy number is also checked for safety. Too many copies raise the risk of insertional mutagenesis that breaks the original genes, so it is watched to see whether it is in the appropriate range.
Confirms that the correct gene is present, that it functions properly, and how many copies enter each cell. Important for both product identity and safety (excess copies carry insertional mutagenesis risk).
Alternatives in practice
- Integration analysis by Southern blot · Electrophoresis + membrane transfer apparatus (Bio-Rad Trans-Blot) + labeled probe — Classical confirmation of integration pattern/copy number. Poor in sensitivity and time
- Insertion site / sequence identity by next-generation sequencing · Illumina MiSeq / NextSeq or Oxford Nanopore MinION (LM-PCR / full-length analysis) — High-resolution insertion site profile and sequence identity. An analysis pipeline is required
- Confirmation of the transgene product by western blot / ELISA · Bio-Rad ChemiDoc / Jess (ProteinSimple) or ELISA reader (SpectraMax) — Confirms the presence and amount of the expressed protein. Depends on antibody availability
Presence of replication-competent lentivirus (RCL) (RCL testing)
Confirms the absence of self-replicating virus; one of the most important safety tests for integrating vectors, required by regulation.
- Standard method
- Cell-based RCL assay using permissive cells
- Makers
- Bio-Rad, IDT, Takara, Applied Biosystems
Why it is the standard. The FDA guidance (January 2020, Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus) recommends RCL testing for each lot of transduced cells. The guidance is a recommendation, not a legal requirement, and the scope of testing varies with the product and application category. A cell-based amplification assay is standard (up to 6 weeks). VSV-G qPCR is a rapid alternative, but care is needed about false positives from residual VSV-G plasmid DNA.
Check also. Replication-competent lentivirus (RCL) testing is required by regulation, and the cell-based amplification assay (up to 6 weeks) is the reference method. Note that the VSV-G gene qPCR, a rapid alternative, can pick up residual VSV-G plasmid DNA and give false positives.
With Stable producer cell line (inducible)
- Because plasmid and PEI are not used, the corresponding residual impurity items disappear, and instead the residual inducer must be controlled, so the analytical panel changes.
- Method: Quantification of residual plasmid DNA and residual PEI can be omitted, and confirmation of removal and quantification of residual inducers (doxycycline/cumate, or sodium butyrate) are added. Quantification of residual host cell DNA and HCP is common to both modes.
- Reagents: Methods for quantifying residual inducers such as doxycycline (LC-MS/MS, etc.)
- Check also: Residual doxycycline is an antibiotic, and its removal and a specification limit in the final drug product are required.
About this step and the alternatives
A test that serves as a fortress of safety, confirming that no virus that multiplies on its own power (replication-competent lentivirus = RCL) is mixed in.
The procedure is a cell-based test: the sample is added to permissive cells in which virus grows easily, and the culture is watched for signs of growth. If none appear, the result is negative.
For vectors of the type that integrate into genes, this is one of the most important safety tests. It is regarded as required by regulation and is a gate before delivery to patients.
Confirms that no virus capable of self-replication has contaminated the product. For integrating vectors it is one of the most important safety tests, and it is also required by regulation.
Alternatives in practice
- RT-qPCR for alternative targets such as psi-gag · Bio-Rad CFX96 / QuantStudio + psi-gag / recombination junction TaqMan assays — Molecularly detects RCL-specific sequences. Assay sensitivity and specificity must be verified
- Extended culture + p24 monitoring (293T-based) · Serial passage amplification in permissive cells + Takara Lenti-X p24 Rapid Titer ELISA (SpectraMax reader) — Captures amplification of replication-competent virus. Takes time because of long-term culture
- Supplementary confirmation by product-enhanced RT (PERT/SG-PERT) systems · Real-time PCR (CFX96 / QuantStudio) + SG-PERT reagents — Screens for replication competence by RT activity. A confirmatory test is separately required
Residual impurities (host cell DNA, proteins, residual reagents) (residual impurities)
Confirms that host DNA, proteins and process-derived reagents are removed to within specification, supporting purity and the clearance capability of the process.
- Standard method
- Quantification of residual host cell DNA by qPCR/ddPCR; quantification of residual HCP and residual reagents by ELISA
Why it is the standard. As a guide, residual DNA is generally <10 ng per 1 dose with fragments <200 bp. Quantification of residual DNA by qPCR/ddPCR and of HCP and residual reagents by ELISA is the industry standard. HCP reduction of about 13,000-fold and residual nucleic acid below the detection limit have been reported as achievable in the process.
About this step and the alternatives
A test that confirms that the "contaminants" that must not remain in the product have been removed to within specification. Safety and purity are supported with numbers.
The targets are the DNA of the host cells (quantified by qPCR/ddPCR), the proteins of the host cells, and reagents used in the process such as Benzonase and BSA (quantified by ELISA).
If these are below the criteria, it is also evidence that the purification steps are properly removing impurities. It is an indicator that shows the cleanliness of the product and the removal capability of the process at the same time.
Confirms that host cell DNA and proteins and process-derived substances such as Benzonase and BSA have been removed to within specification. It is an indicator of safety and purity and supports the clearance capability of the process.
Alternatives in practice
- Total DNA quantification by threshold / fluorescent dye methods · Thermo Fisher Qubit 4 Fluorometer + Quant-iT PicoGreen dsDNA Assay (P7589) — Simple quantification of total dsDNA. Not sequence-specific, so unsuitable for host DNA-specific measurement
- Confirmation of residual protein by SDS-PAGE / western · Bio-Rad Criterion/ChemiDoc or ProteinSimple Jess — Qualitative confirmation of residual HCP / specific proteins. Less sensitive than ELISA
- Fragment length analysis (capillary electrophoresis) · Agilent 2100 Bioanalyzer / 4200 TapeStation or Agilent Fragment Analyzer — Evaluates fragment length and distribution of residual DNA/RNA. Useful for confirming nuclease digestion
Sterility, endotoxin, mycoplasma and adventitious agents (sterility / endotoxin, etc.)
An essential group of tests, a prerequisite for administration to patients, confirming sterility and the absence of endotoxin, mycoplasma and adventitious viruses.
- Standard method
- USP <71>/EP sterility test, LAL
Why it is the standard. 21 CFR 610.12/USP <71> for sterility, USP <85>/LAL for endotoxin and USP <63> for mycoplasma are the regulatory standards. For CGT products with a short half-life, early determination by rapid PCR methods (e.g., MycoSEQ) is widely used.
About this step and the alternatives
A group of safety tests that confirm the basic premise of whether the product is safe to put into the body as an injectable. They are examined by USP/EP sterility tests, LAL endotoxin tests and others.
What is checked is that no microorganisms are present, that no endotoxin, which causes fever, is present, and that no mycoplasma or adventitious viruses are mixed in. A negative result is required in every case.
If even one of them fails, the product cannot be administered to patients. This group of tests is an indispensable gate that decides pass or fail for shipment.
Confirms that the product is safe as an injectable, free of microorganisms, endotoxin, mycoplasma and adventitious viruses. An essential group of safety tests that is a prerequisite for administration to patients.
Alternatives in practice
- Rapid sterility test (alternative methods such as CO2/ATP-based) · bioMérieux BACT/ALERT 3D (CGT) or Rapid Micro Biosystems Growth Direct — Short turnaround suits CAR-T and others. Validation of the alternative method (equivalence) is required
- rFC (recombinant Factor C) endotoxin method · Lonza PyroGene Recombinant Factor C Assay (fluorescence) + fluorescence plate reader (SpectraMax/CLARIOstar) — No animal-derived material, and no glucan reactivity, reducing false positives. Sensitivity equivalent to LAL
- In vitro adventitious virus assay / transmission electron microscopy (TEM) · Indicator cell culture + observation of cytopathic effect; TEM: JEOL/Thermo Fisher (FEI) transmission electron microscope — Detects adventitious agents and confirms particle morphology. Requires specialized equipment and time
Physical properties such as particle size, aggregation and empty/full particle ratio (particle characteristics / NTA)
Measures particle size, aggregation and the full-particle ratio to physically support their effects on stability and infectivity, together with other methods.
- Standard method
- Particle size distribution and particle concentration by nanoparticle tracking analysis (NTA) (used together with other methods)
- Equipment
- Nanoparticle tracking analysis, DLS, TEM negative stain capsid
- Reagents and materials
- — (only dilution buffer for particle measurement, e.g., 0.22 μm-filtered PBS). For fluorescence NTA, membrane labeling dyes (e.g., lipophilic carbocyanines such as Thermo Fisher DiO/DiI) are used as needed.
Why it is the standard. NTA is a representative method that measures hydrodynamic diameter, size distribution and particle concentration from the scattered light of Brownian motion, has many applications to LV products and correlates with VCN (r²≈0.80). A single method has limits, and combining it with methods of other principles or complementary methods such as DLS, TRPS and electron microscopy is recommended.
Check also. Nanoparticle tracking analysis (NTA) can directly measure particle size distribution and particle concentration, but a single method has limits, for example in distinguishing empty and full particles. It is supported by combining methods of different principles such as dynamic light scattering (DLS), tunable resistive pulse sensing (TRPS) and electron microscopy.
About this step and the alternatives
A test that physically looks at the "workmanship" of the vector as particles. The particle size distribution and concentration are measured by nanoparticle tracking analysis (NTA) and others.
What can be learned here is particle size, the presence of clumps (aggregation), and how many full particles with filled contents there are. Several methods are used together to confirm from multiple sides.
The state of the particles is directly tied to stability during storage and infectivity. It is an indicator that supports, from a physical angle separate from efficacy, whether the formulation and process are going well.
Looks at particle size, the presence of aggregation, and the proportion of particles whose contents are filled. These affect stability and infectivity, so they physically support whether the formulation and process are good.
Alternatives in practice
- DLS · Malvern Panalytical Zetasizer Advance (Pro/Ultra) or Wyatt DynaPro — Gives mean particle size and polydispersity simply. Cannot count individual particles or give concentration
- Tunable resistive pulse sensing (TRPS) · Izon Science qNano Gold / Exoid — Measures size, concentration and surface charge of individual particles. Watch for nanopore clogging
- Transmission electron microscope (TEM) · TEM such as JEOL JEM / Thermo Fisher (FEI) Talos (negative stain / cryo) — Directly observes morphology and empty/full capsid ratio. Low in quantitation and throughput
The reference (“gold standard”) method is the one broadly recognized in published practice and guidelines; your process, product and regulator may justify another. Makers and products are examples, not endorsements. This map is translated from the Japanese edition, where it is updated first (Japanese version).